Latest News

AI, real-world data, and patient voices reshape pharmacovigilance, helping pharmacists spot risks faster and strengthen lifecycle drug safety.

Octogenarians with early-stage non–small cell lung cancer (NSCLC) can safely undergo surgery and achieve survival and quality-of-life outcomes comparable to younger patients.

AI is reshaping pharmacy, from catching dangerous drug interactions to personalizing chemotherapy dosing.

New analysis suggests oral semaglutide may offer improved efficacy and tolerability compared with orforglipron, informing treatment selection in an increasingly competitive oral GLP-1 landscape.

Review finds prior authorizations delay neurologic treatment, trigger relapses, and intensify clinician burnout, spurring calls for rapid reform.

Team-based, multidisciplinary care aids personalized treatment, improving coordination across complex therapies, and enhances patient outcomes and long-term quality of life.

The first-in-class triple agonist met all primary and key secondary end points in the TRANSCEND-T2D-1 trial.

The National Association of Boards of Pharmacy (NABP) opens the door to the Occupational English Test (OET) as an alternative English exam for foreign pharmacy graduate certification.

Circulating tumor DNA detected after neoadjuvant therapy may serve as a powerful biomarker for minimal residual disease and help predict breast cancer recurrence.

Data from a new 20-year analysis reveal persistent inequities in influenza vaccination among a high-risk cardiovascular population.

Pharmacy supply chain disruptions directly shape the treatment that patients receive, making it vital that pharmacists understand the causes and consequences of delays.

Brandon Welch, PharmD, highlights the expanding role of sports pharmacists in medication safety, anti-doping, and personalized athlete care.

Pulse by NABP is revolutionizing drug supply chain oversight and patient safety.

AHA Epidemiology Sessions 2026 show that chronic kidney disease (CKD) proteinuria drops of 30% or more cut heart failure, major adverse cardiovascular events, and death, a key prevention signal.

As pharmacy technology consolidates under a few powerful platforms, independent pharmacies risk losing control of the data—and leverage—they generate every day.

The approval is supported by clinical data from the ATTAIN-1 and ATTAIN-2 trials.

The updated dosing schedule for nusinersen offers increased drug exposure and may further improve outcomes for patients with spinal muscular atrophy.

There was limited evidence supporting additional clinical benefits.

Jonathan Leung, PharmD, RPh, BCPS, discusses the ongoing underutilization of clozapine despite its efficacy, highlighting clinician concerns, lingering perceptions, and the key role pharmacists play in improving its use through education and monitoring.

Fluvoxamine significantly reduced fatigue in adults with long COVID, with a 99% probability of outperforming placebo.